8Uehino K, Alexandrov AV, Garami Z, et al. Safety and feasibility of a lower dose intravenous TPA therapy for ischemicstroke beyond the first three hours[J]. Cerebrovasc Dis, 2005,19(4) : 260-266.
3[12]Asahi M,Asahi K,Wang X,et al.Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats[J].J Cereb Blood Flow Metab,2000,20:452-457.
4[13]Kano T,Katayama Y,Tejima E,et al.Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke[J].Brain Res,2000,854:245-248.
5[14]Nagai N,De Mol M,Lijnen HE,et al.Role of plasminogen system components in focal cerebral ischemic infarction:a gene targeting and gene transfer study in mice[J].Circulation,1999,99:2440-2444.
6[15]Ribo M,Montaner J,Molina CA.et al.Admission fibrinolytic profile is associated tiwh symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator[J].Stroke,2004,35:2123-2127.
7[16]Hu B,Liu C,Zivin JA.Reduction of intracerebral hemorrhaging in a rabbit embolic stroke model[J].Neurology,1999,53:2140-2145.
8[17]Morita-Fujimura Y,Fujimura M,Gasche Y,et al.Overexpression of copper and zinc superoxide dismutase in transgenic mice prevents the induction and activation of matrix metalloproteinases after cold injury induced brain trauma[J].J Cereb Blood Flow Metab,1999,20:130-138.
10[19]Sumii T,Lo EH.Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats[J].Stroke,2002,33:831-836.
